This study reveals the critical role of PLA2G2A in resistance to immunotherapy for gastric cancer, providing new experimental design insights for patient screening and combination therapy strategies for gastric cancer patients.
Literature Overview
The article "Gastric cancer tertiary lymphoid structures in the muscularis propria are associated with therapy resistance and promote immunosuppression," published in Nature Communications, systematically explores the spatial heterogeneity of tertiary lymphoid structures (TLS) in gastric cancer and their impact on immunotherapy response. By integrating histopathology, spatial transcriptomics, and single-cell sequencing technologies, the study found that while TLS in the muscularis propria are increased in number, they exhibit structural disorganization and functional impairment, which are key factors leading to resistance against anti-PD-1 therapy.Background Knowledge
1. The pain point addressed by this study in gastric cancer is that, although immune checkpoint inhibitors (such as anti-PD-1 therapy) have transformed the tumor treatment landscape, over 60% of advanced patients still exhibit primary or acquired resistance, with a lack of effective predictive biomarkers.
2. The current bottleneck in TLS research lies in the prevailing view that the mere presence of TLS is always beneficial, overlooking the differential impacts of their spatial location (e.g., mucosal layer vs. muscularis propria) and maturation status (e.g., germinal center formation) on immune function.
3. The research切入点 focuses on the muscularis propria as a specific anatomical region to investigate why TLS accumulation here correlates with poor prognosis, and to deeply explore the molecular mechanisms driving this dysfunction, particularly the interaction network between tumor cells and stromal cells.
Research Methods and Core Experiments
The authors adopted a multi-omics integration strategy. First, they performed H&E morphological assessment and multiplex immunofluorescence staining on surgical specimens from 71 gastric cancer patients who received neoadjuvant anti-PD-1 therapy and chemotherapy, precisely quantifying TLS density and area across different anatomical layers (mucosa, submucosa, muscularis propria, serosa). Subsequently, using spatial transcriptomics (10x Visium) and single-cell RNA sequencing (scRNA-seq), they deeply analyzed differences in cellular composition and gene expression between the resistant group (PD) and the responder group (CR/PR).
Key evidence chains include: In vitro co-culture experiments verified that the PLA2G2A protein induces the differentiation of fibroblasts into PDGFRA+ inflammatory cancer-associated fibroblasts (iCAFs) and promotes the secretion of CXCL14; Transwell migration assays confirmed the chemotactic effect of CXCL14 on naive B cells; finally, flow cytometry and RNA-seq demonstrated that PLA2G2A directly inhibits B cell differentiation and induces follicular helper T cell (Tfh) death, thereby blocking germinal center reactions.Key Conclusions and Perspectives
Research Significance and Prospects
From a research perspective, this finding has direct implications for drug development, suggesting future development of small molecule inhibitors or neutralizing antibodies targeting PLA2G2A, to be used in combination with immune checkpoint inhibitors.
In terms of clinical monitoring, it is recommended to incorporate spatial distribution characteristics of TLS (especially muscularis propria infiltration) and maturity into pathological assessment systems to optimize patient stratification.
Regarding disease modeling, this study suggests that when constructing gastric cancer immunotherapy resistance models, special attention must be paid to the interactions between stromal cells and B cells in the tumor microenvironment, as well as the regulatory role of PLA2G2A.
Conclusion
This study fundamentally challenges the traditional notion that "tertiary lymphoid structures inevitably promote anti-tumor immunity," revealing the functional heterogeneity of TLS in the muscularis propria of gastric cancer and their negative role in immunotherapy resistance. By dissecting the PLA2G2A-mediated tumor-stroma-immune cell interaction axis, the research not only elucidates the molecular mechanism by which naive B cells fail to differentiate into effector cells but also provides a novel target for overcoming the bottleneck of gastric cancer immunotherapy. From laboratory discovery to clinical translation, intervention strategies targeting PLA2G2A are expected to reshape the tumor immune microenvironment, restore TLS function, and significantly enhance the efficacy of anti-PD-1 therapy. This discovery lays a solid theoretical and experimental foundation for constructing more precise combination immunotherapy regimens for gastric cancer and developing novel biomarkers, holding profound clinical value for improving the survival prognosis of patients with advanced gastric cancer.
